Neratinib

Research use only, not for human use.

A potent, highly selective, irreversible HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays.

A potent, highly selective, irreversible HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays; weakly inhibits KDR and Src (IC50=0.8 and 1.4 uM), no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met; inhibits downstream signal transduction events and cell cycle regulatory pathways, leads to arrest at the G(1)-S phase transition, decreases cell proliferation; active in HER-2- and EGFR-dependent tumor xenograft models, orally bioavailable.Breast Cancer Approved

HKI-272;HKI272;HKI 272

Angiogenesis

EGFR

EGFR;HER2;PDK1;Src;VEGFR2(KDR)

Cancer

Breast Cancer

698387-09-6

557.04

C30H29ClN6O3

>98% (HPLC)

DMSO: 6.4 mg/mL (Need ultrasonic)

CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C

2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)-

(-20℃)

With Ice Pack

≥ 2 years